A Study of N-Acetylcysteine (N-AC) in People Receiving CAR T-cell Therapy for Lymphoma

Inclusion Criteria:

• Patients must be 18 years of age or older

• Patients who will receive axicabtagene ciloleucel for treatment of lymphoma

• Patients must have adequate end organ function to be eligible for this study asdefined by the following criteria:

• ECOG performance status 0-2

• Hematologic function with ANC ≥ 1000, Hgb ≥ 8, Plt ≥ 50k unless there isdisease related hematologic toxicity

• Renal function with CrCr ≥ 40 ml/min or Cr ≤ 1.5 x ULN

• Hepatic function with ALT/AST ≤ 2.5 x ULN, TBili ≤ 1.5 x ULN.

Exclusion Criteria:

• Patients with known allergy to N-AC